PARP inhibition and DNA Damage Response (DDR)

The information on the site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

This site contains information and education for healthcare professionals.

This section has been developed as a resource providing information on PARP inhibition and DNA Damage Response (DDR) as therapeutic targets across multiple tumour types.

Information included in this website is compiled from review of the medical literature and expert guidance from Simon Boulton (The Francis Crick Institute, London; and Artios Pharma Ltd., Cambridge, UK), Judith Balmaña (Vall d’Hebron Institute of Oncology, and Vall d’Hebron University Hospital, Barcelona, Spain), Charlie Gourley (Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, UK) and Violeta Serra (Vall d’Hebron Institute of Oncology, Barcelona, Spain).

Find more about the learning objectives.

There are two modules. Click on the links below to find out more on PARP inhibition and the DNA Damage Response (DDR) pathway. We recommend that Module 1 is selected first, but the modules can be selected in any order. 


Module 1 PARP inhibition


Module 2 DNA Damage Response

This module provides an overview of PARP inhibition (PARPi).

Access now

This module provides an overview of DNA Damage Response (DDR).

Access now


By pursuing, you confirm that you have read and understand the disclaimer

Table of Contents